Clinical Research Directory

Inclusion Criteria: 1. Male or female patients, aged 18 to 75 years; 2. patients with malignant solid tumors confirmed by pathology and/or cytology who have progressed or are intolerant to standard treatment (except best supportive care); Including patients who have received prior anti-PD-1 antibody therapy; patients who have been approved as eligible for Toripalimab: 3. General condition score ECOG 0 \~ 1; 4. Expected survival of more than 3 months; Exclusion Criteria: 1. Known or suspected allergy to the ingredients of the study drug or its analogues; allergic history to another monoclonal antibody; 2. patients who have previously received IL-12 therapy (alone or as part of a treatment regimen), except those who have participated in tolerance to a single intratumoral injection; 3. patients who have previously received treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or have received treatment directed at another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137), and discontinued treatment due to Grade 3 or higher immune-related adverse events (irAEs);